IE
LYEL icon

Israel Englander’s Lyell Immunopharma LYEL Stock Holding History

Israel Englander’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Sell
367,473
-91,432
-20% -$1.65M ﹤0.01% 2975
2026
Q1 		$9.21M Buy
458,905
+400,254
+682% +$9.36M ﹤0.01% 2251
2025
Q4 		$1.81M Sell
58,651
-66,710
-53% -$1.49M ﹤0.01% 4034
2025
Q3 		$2.04M Buy
125,361
+73,132
+140% +$835K ﹤0.01% 4046
2025
Q2 		$462K Buy
52,229
+50,081
+2,332% +$456K ﹤0.01% 4958
2025
Q1 		$23.1K Sell
2,148
-45,727
-96% -$560K ﹤0.01% 5617
2024
Q4 		$613K Buy
47,875
+12,372
+35% +$245K ﹤0.01% 4582
2024
Q3 		$980K Sell
35,503
-4,975
-12% -$146K ﹤0.01% 4297
2024
Q2 		$1.17M Sell
40,478
-61,356
-60% -$2.92M ﹤0.01% 3996
2024
Q1 		$4.54M Buy
101,834
+56,883
+127% +$2.44M ﹤0.01% 2954
2023
Q4 		$1.74M Buy
44,951
+35,175
+360% +$1.27M ﹤0.01% 3720
2023
Q3 		$287K Sell
9,776
-658
-6% -$31.2K ﹤0.01% 4951
2023
Q2 		$664K Sell
10,434
-6,864
-40% -$380K ﹤0.01% 4343
2023
Q1 		$816K Buy
+17,298
New +$925K ﹤0.01% 4279
2022
Q2 		– Sell
-14,093
Closed -$1.42M – 7266
2022
Q1 		$1.42M Sell
14,093
-5,326
-27% -$645K ﹤0.01% 4175
2021
Q4 		$3.01M Buy
19,419
+16,143
+493% +$3.6M ﹤0.01% 3382
2021
Q3 		$970K Sell
3,276
-3,282
-50% -$983K ﹤0.01% 4725
2021
Q2 		$2.13M Buy
+6,558
New +$2.15M ﹤0.01% 3888

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Israel Englander's LYEL Position: Q2 2026 in Review

Israel Englander reduced its Lyell Immunopharma (LYEL) stake by 20% in Q2 2026, selling an estimated $1.65M and leaving 367,473 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2975.

Israel Englander first reported a position in LYEL in Q2 2021 and has held it in 18 quarters since. The position peaked at $9.21M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Israel Englander held 367,473 shares of Lyell Immunopharma worth $5.16M as of Q2 2026.
  • Israel Englander sold 91,432 Lyell Immunopharma shares in Q2 2026, an estimated $1.65M.
  • Lyell Immunopharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2975 holding.
  • Israel Englander first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 18 quarters since.
  • Israel Englander's Lyell Immunopharma position peaked at $9.21M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.